Boule Diagnostics

Interim Report
Q3 2022

Financial Highlights

NET SALES, MSEK
125.6
GROSS MARGIN
40.7
%
OPERATING PROFIT, MSEK
3.6
OPERATIONAL CASH FLOW, MSEK
-15.8
Jesper

A challenging third quarter

Sales increased by 12 percent to SEK 126 million. Adjusted for exchange rates, organic growth decreased by 8.1 percent. This decrease is due to the challenging market conditions and shortage of electronic components for production of instrument during July and August that we were unable to recover during September. 

CEO COMMENTS

Net sales by region

Net sales by product

Near-patient diagnostics

Complete Blood Count (CBC) is the most common test for in vitro diagnostics. In 2019, the decentralized and patient-related hematology segment had an estimated market value of just over SEK 6 billion, while the corresponding segment for the veterinary market was valued at approximately SEK 2.6 billion

Map En

100
+

Countries

SEK
9
BILLION

Human and veterinary market

140
MILLION

Tests per year

TO THE REPORT

ABOUT BOULE DIAGNOSTICS

Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.